Dimensional Fund Advisors LP Kinnate Biopharma Inc. Transaction History

Dimensional Fund Advisors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.24 - $2.66 $173,304 - $205,798	77,368 Added 530.17%	91,961 $244,000
Q4 2023 Feb 07, 2024	BUY	$1.07 - $2.5 $2,508 - $5,860	2,344 Added 19.14%	14,593 $34,000
Q3 2023 Nov 09, 2023	SELL	$1.38 - $3.31 $18,402 - $44,138	-13,335 Reduced 52.12%	12,249 $17,000
Q2 2023 Aug 09, 2023	SELL	$2.33 - $6.84 $16,221 - $47,620	-6,962 Reduced 21.39%	25,584 $77,000
Q1 2023 May 12, 2023	SELL	$3.46 - $7.98 $20,247 - $46,698	-5,852 Reduced 15.24%	32,546 $203,000
Q4 2022 Feb 09, 2023	SELL	$5.26 - $12.19 $2,682 - $6,216	-510 Reduced 1.31%	38,398 $234,000
Q3 2022 Nov 10, 2022	BUY	$9.86 - $15.76 $74,097 - $118,436	7,515 Added 23.94%	38,908 $465,000
Q2 2022 Aug 12, 2022	BUY	$7.43 - $13.0 $233,249 - $408,109	31,393 New	31,393 $396,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.